CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 142 enrolled
Drug / intervention
Ranolazine +1 moredrug
Likely dose
Ranolazine 1,000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01342029
NCT01342029N/ACompleted
CompareCT.gov

Treatment With Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina Myocardial Ischemia

Cedars-Sinai Medical Center·interventional·Posted Apr 26, 2011·Updated Apr 24, 2019

In Brief

A clinical study evaluating Ranolazine and Placebo for Microvascular Coronary Dysfunction (MCD). Completed, enrolled 142 participants across 2 sites.

Detailed Summary

This research study is designed to test the use of ranolazine in patients with angina (chest discomfort due to reduced blood supply to the heart) due to microvascular coronary dysfunction (MCD; abnormalities in the small blood vessels of the heart). This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina. The FDA has approved this drug based on studies primarily on patients with chronic angina with major blockages of the arteries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMicrovascular Coronary Dysfunction (MCD)
CountriesUnited States
CollaboratorsUniversity of Florida

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedApr 26, 2011
Enrollment StartMay 1, 2011
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.2 years ago

Interventions

Ranolazinedrug

This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina. 500-1,000 mg po bid for 2 weeks

Placebodrug

500-1,000 mg po bid for 2 weeks